Figure 2.

Association between any cancer risk and cumulative exposure to integrase strand transfer inhibitors (INSTIs), adjusted for potential confounders. Incidence rate ratio (IRR) adjusted for age, sex, ethnicity, human immunodeficiency virus risk group, antiretroviral treatment experience, CD4 cell count, CD4 nadir, body mass index, geographical region, hepatitis B, prior diabetes, prior acquired immune deficiency syndrome, prior cancer, prior chronic kidney disease, prior cardiovascular disease, prior end-stage liver disease (all fixed at baseline), smoking status (time updated). Note, INSTI exposure is lagged by 6 months. CI, confidence interval; PYFU, person years of follow-up.